InMed Pharmaceuticals entered into amending agreements with Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC. The agreements reduce the exercise price for a total of 2,304,714 potential common shares to $0.80 per share. The Sabby options were previously priced at $2.436 per share. The Wainwright options were previously priced at various levels, including $82.50, $20.75, and $3.2013 per share on a post-consolidation basis. These amendments were formalized on April 21, 2026, for Sabby and April 24, 2026, for Wainwright.